---
company: Covista Inc.
ticker: CVSA
form: 8-K
filed: 2026-08-06
accession: 0000730464-26-000037
source: https://www.sec.gov/Archives/edgar/data/730464/000073046426000037/
---

# Covista (CVSA) earnings release, August 6, 2026

Covista Inc. (CVSA) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/730464/000073046426000037/)

Investor Contact:

Jeremy Cohen

Investor.Relations@Covista.com

+1 312-906-6600

​

Media Contact:

Maureen Bender

CovistaMedia@Covista.com

+1 313-319-4732

Covista Announces Fiscal Year 2026 Results, Exceeds Financial Guidance;

Initiates Fiscal Year 2027 Guidance

Total Q4 enrollment up 8.4% and revenue up 9.7% YoY

Chamberlain accelerates total enrollment growth to 1.6%

Revenue up 9.3% YoY for fiscal year 2026

Fiscal year 2026 diluted earnings per share $7.04; Adjusted EPS $8.25, growth of 23.7% YoY

Fourth quarter highlights

Fiscal year highlights

Fiscal year capital allocation

Fiscal year 2027 guidance

​

​

CHICAGO – August 6, 2026 – Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported fourth quarter and fiscal year 2026 results (ended June 30, 2026). The Company completed its three-year

Growth with Purpose strategy and now embarks on its

Purpose at Scale strategy, leading the transformation of higher education by training the next generation of healthcare professionals at an industry-leading scale.

"We completed

Growth with Purpose in a position of strength, exceeding both our fiscal 2026 and long-term financial targets. The strategy produced exactly what it was designed to deliver: compounding returns built on sustained investment, deliberate positioning, and a relentless focus on student outcomes. But the results go beyond the financial. They reflect a deeper transformation and vision to be the destination where healthcare ambitions are made possible, graduating professionals who don't just fill jobs, but strengthen the communities where they serve,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “We enter our next chapter,

Purpose at Scale, powered by an operating model that converts durable healthcare demand into sustainable, profitable growth. Applying that discipline to a larger opportunity is how we create value for our stakeholders and help close the healthcare workforce shortage the country urgently needs solved."

Financial Highlights

Selected financial data for the three months ended June 30, 2026:

Selected financial data for the fiscal year ended June 30, 2026:

​

Business Highlights

Segment Highlights

Chamberlain

​

​

Walden

​

​

Medical and Veterinary

​

​

Fiscal Year 2027 Outlook

Covista initiates guidance for fiscal year 2027, including:

​

“We are entering the first year of

Purpose at Scale with enhanced momentum, reflecting our strong finish to fiscal year 2026. The overall financial performance trajectory allows us to provide compelling guidance for fiscal year 2027. Taken together, we are tracking ahead of where we expected we would be with regard to our long-term targets,” said Beard.

​

Conference Call and Webcast Information

Covista will hold a conference call to discuss its fourth quarter and fiscal year 2026 results today at 4:00 p.m. CT (5:00 p.m. ET).

​

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13761006. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com.

​

Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13761006, or visit the Covista investor relations website.

​

About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit Covista.com and follow us on LinkedIn, Instagram and YouTube.

​

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,”

“expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you... (truncated)perience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

​

A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP.

###

​

Covista Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands)

​

​

​

​

​

​

​

​

Covista Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​

​

​

​

​

Covista Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Segment Revenue

(unaudited)

(in thousands)

​

​

​

Covista Inc.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, tax benefit due to change in unrecognized tax benefits, and loss (income) from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, tax benefit due to change in unrecognized tax benefits, and loss (income) from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.

Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.

Net debt – Defined as total long-term debt principal less cash and cash equivalents.

Net leverage – Defined as net debt divided by adjusted EBITDA.

A description of special items in our non-GAAP financial measures described above are as follows:

Covista Inc.

Adjusted Operating Income

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Adjusted EBITDA

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Adjusted Earnings

(unaudited)

(in thousands, except per share data)

​

(1)

Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

​

Note: May not sum due to rounding.

(1)

Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

​

Covista Inc.

Free Cash Flow

(unaudited)

(in thousands)

​

​

​

​

​

Covista Inc.

Net Leverage

(unaudited)

(in thousands)

​

​

## Financial statements

### Income Statement (Three Months Ended — Chamberlain (in millions))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Three Months Ended – June 30, – % Change | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | Year Ended – June 30, – % Change |
|---|---:|---:|---:|---:|---:|---:|
| Revenue | 190.2 | 184.3 | 3.2% | 750.2 | 725.8 | 3.4% |
| Operating Income | 36.3 | 35.7 | 1.6% | 141.6 | 151.5 | -6.5% |
| Adj. Operating Income | 36.3 | 35.7 | 1.6% | 143.6 | 153.4 | -6.3% |
| Adj. EBITDA | 46.8 | 45 | 3.8% | 185.5 | 191.4 | -3.1% |
| Total Students (2) | 39,501 | 38,891 | 1.6% |  |  |  |

### Income Statement (Three Months Ended — Walden (in millions))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Three Months Ended – June 30, – % Change | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | Year Ended – June 30, – % Change |
|---|---:|---:|---:|---:|---:|---:|
| Revenue | 210.8 | 182.2 | 15.7% | 804.9 | 693.4 | 16.1% |
| Operating Income | 59.8 | 44 | 35.9% | 227.8 | 177.9 | 28.0% |
| Adj. Operating Income | 62.8 | 46.8 | 34.3% | 239.7 | 183.6 | 30.6% |
| Adj. EBITDA | 69.7 | 52.7 | 32.3% | 268 | 206.5 | 29.8% |
| Total Students (2) | 54,851 | 48,116 | 14.0% |  |  |  |

### Income Statement (Three Months Ended — Medical and Veterinary (in millions))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Three Months Ended – June 30, – % Change | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | Year Ended – June 30, – % Change |
|---|---:|---:|---:|---:|---:|---:|
| Revenue | 100.3 | 90.6 | 10.7% | 398.9 | 369.1 | 8.1% |
| Operating Income | 16.7 | 14.9 | 12.1% | 79.1 | 68.8 | 15.0% |
| Adj. Operating Income | 16.7 | 15.1 | 10.4% | 80 | 69.3 | 15.5% |
| Adj. EBITDA | 22.5 | 20 | 12.3% | 102.8 | 88.8 | 15.7% |
| Total Students (2) | 5,120 | 4,773 | 7.3% |  |  |  |

### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 501,382 | 457,106 | 1,954,085 | 1,788,290 |
| Operating cost and expense: | Cost of educational services | 216,749 | 198,930 | 833,660 | 771,430 |
| Operating cost and expense: | Student services and administrative expense | 188,089 | 180,863 | 730,720 | 672,004 |
| Operating cost and expense: | Restructuring expense | 1,101 | 388 | 6,329 | 3,314 |
| Operating cost and expense: | Total operating cost and expense | 405,939 | 380,181 | 1,570,709 | 1,446,748 |
| Operating cost and expense: | Operating income | 95,443 | 76,925 | 383,376 | 341,542 |
| Operating cost and expense: | Interest expense | -9,799 | -10,853 | -45,435 | -52,318 |
| Operating cost and expense: | Other income, net | 2,756 | 2,511 | 7,178 | 9,290 |
| Operating cost and expense: | Income from continuing operations before income taxes | 88,400 | 68,583 | 345,119 | 298,514 |
| Operating cost and expense: | Provision for income taxes | -16,240 | -14,121 | -77,744 | -65,837 |
| Operating cost and expense: | Income from continuing operations | 72,160 | 54,462 | 267,375 | 232,677 |
| Discontinued operations: | (Loss) income from discontinued operations before income taxes | -426 | -346 | -21,236 | 5,870 |
| Discontinued operations: | (Provision for) benefit from income taxes | -13 | 96 | 5,427 | -1,482 |
| Discontinued operations: | (Loss) income from discontinued operations | -439 | -250 | -15,809 | 4,388 |
| Discontinued operations: | Net income and comprehensive income | 71,721 | 54,212 | 251,566 | 237,065 |
| Basic: | Continuing operations | 2.12 | 1.51 | 7.63 | 6.27 |
| Basic: | Discontinued operations | -0.01 | -0.01 | -0.45 | 0.12 |
| Basic: | Total basic earnings per share | 2.11 | 1.5 | 7.18 | 6.39 |
| Diluted: | Continuing operations | 2.08 | 1.45 | 7.49 | 6.07 |
| Diluted: | Discontinued operations | -0.01 | -0.01 | -0.44 | 0.11 |
| Diluted: | Total diluted earnings per share | 2.06 | 1.44 | 7.04 | 6.18 |
| Weighted-average shares outstanding: | Basic shares | 34,032 | 36,034 | 35,045 | 37,085 |
| Weighted-average shares outstanding: | Diluted shares | 34,763 | 37,584 | 35,715 | 38,334 |

### Income Statement (Three Months Ended — (in thousands))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Three Months Ended – June 30, – Increase/(Decrease) – $$ | Three Months Ended – June 30, – Increase/(Decrease) – % | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | Year Ended – June 30, – Increase/(Decrease) – $$ | Year Ended – June 30, – Increase/(Decrease) – % |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Chamberlain: | Operating income | 36,316 | 35,739 | 577 | 1.6% | 141,618 | 151,455 | -9,837 | -6.5% |
| Chamberlain: | Restructuring expense |  |  |  |  | 2,024 | 1,912 | 112 |  |
| Chamberlain: | Adjusted operating income | 36,316 | 35,739 | 577 | 1.6% | 143,642 | 153,367 | -9,725 | -6.3% |
| Chamberlain: | Operating margin | 19.1% | 19.4% |  |  | 18.9% | 20.9% |  |  |
| Chamberlain: | Adjusted operating margin | 19.1% | 19.4% |  |  | 19.1% | 21.1% |  |  |
| Walden: | Operating income | 59,753 | 43,982 | 15,771 | 35.9% | 227,788 | 177,911 | 49,877 | 28.0% |
| Walden: | Restructuring expense | 255 |  | 255 |  | 715 |  | 715 |  |
| Walden: | Amortization of acquired intangible assets | 2,805 | 2,805 |  |  | 11,220 | 11,220 |  |  |
| Walden: | Litigation reserve |  |  |  |  |  | -5,550 | 5,550 |  |
| Walden: | Adjusted operating income | 62,813 | 46,787 | 16,026 | 34.3% | 239,723 | 183,581 | 56,142 | 30.6% |
| Walden: | Operating margin | 28.3% | 24.1% |  |  | 28.3% | 25.7% |  |  |
| Walden: | Adjusted operating margin | 29.8% | 25.7% |  |  | 29.8% | 26.5% |  |  |
| Medical and Veterinary: | Operating income | 16,656 | 14,864 | 1,792 | 12.1% | 79,110 | 68,798 | 10,312 | 15.0% |
| Medical and Veterinary: | Restructuring expense |  | 218 | -218 |  | 855 | 454 | 401 |  |
| Medical and Veterinary: | Adjusted operating income | 16,656 | 15,082 | 1,574 | 10.4% | 79,965 | 69,252 | 10,713 | 15.5% |
| Medical and Veterinary: | Operating margin | 16.6% | 16.4% |  |  | 19.8% | 18.6% |  |  |
| Medical and Veterinary: | Adjusted operating margin | 16.6% | 16.6% |  |  | 20.0% | 18.8% |  |  |

### Income Statement (Three Months Ended — (in thousands))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Three Months Ended – June 30, – Increase/(Decrease) – $$ | Three Months Ended – June 30, – Increase/(Decrease) – % | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | Year Ended – June 30, – Increase/(Decrease) – $$ | Year Ended – June 30, – Increase/(Decrease) – % |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Chamberlain: | Adjusted operating income (GAAP) | 36,316 | 35,739 | 577 | 1.6% | 143,642 | 153,367 | -9,725 | -6.3% |
| Chamberlain: | Depreciation | 5,965 | 5,503 | 462 |  | 23,073 | 21,687 | 1,386 |  |
| Chamberlain: | Amortization of cloud computing implementation assets | 2,069 | 780 | 1,289 |  | 7,689 | 3,033 | 4,656 |  |
| Chamberlain: | Stock-based compensation | 2,419 | 3,019 | -600 |  | 11,128 | 13,309 | -2,181 |  |
| Chamberlain: | Adjusted EBITDA (non-GAAP) | 46,769 | 45,041 | 1,728 | 3.8% | 185,532 | 191,396 | -5,864 | -3.1% |
| Chamberlain: | Adjusted EBITDA margin (non-GAAP) | 24.6% | 24.4% |  |  | 24.7% | 26.4% |  |  |
| Walden: | Adjusted operating income (GAAP) | 62,813 | 46,787 | 16,026 | 34.3% | 239,723 | 183,581 | 56,142 | 30.6% |
| Walden: | Depreciation | 2,014 | 1,993 | 21 |  | 8,103 | 7,421 | 682 |  |
| Walden: | Amortization of cloud computing implementation assets | 1,916 | 760 | 1,156 |  | 6,939 | 3,002 | 3,937 |  |
| Walden: | Stock-based compensation | 2,926 | 3,123 | -197 |  | 13,190 | 12,477 | 713 |  |
| Walden: | Adjusted EBITDA (non-GAAP) | 69,669 | 52,663 | 17,006 | 32.3% | 267,955 | 206,481 | 61,474 | 29.8% |
| Walden: | Adjusted EBITDA margin (non-GAAP) | 33.0% | 28.9% |  |  | 33.3% | 29.8% |  |  |
| Medical and Veterinary: | Adjusted operating income (GAAP) | 16,656 | 15,082 | 1,574 | 10.4% | 79,965 | 69,252 | 10,713 | 15.5% |
| Medical and Veterinary: | Depreciation | 3,080 | 2,755 | 325 |  | 12,016 | 10,853 | 1,163 |  |
| Medical and Veterinary: | Amortization of cloud computing implementation assets | 719 | 306 | 413 |  | 2,555 | 1,208 | 1,347 |  |
| Medical and Veterinary: | Stock-based compensation | 2,022 | 1,873 | 149 |  | 8,243 | 7,486 | 757 |  |
| Medical and Veterinary: | Adjusted EBITDA (non-GAAP) | 22,477 | 20,016 | 2,461 | 12.3% | 102,779 | 88,799 | 13,980 | 15.7% |
| Medical and Veterinary: | Adjusted EBITDA margin (non-GAAP) | 22.4% | 22.1% |  |  | 25.8% | 24.1% |  |  |
| Home Office: | Adjusted operating loss | -14,906 | -10,100 | -4,806 | -47.6% | -43,843 | -36,030 | -7,813 | -21.7% |
| Home Office: | Depreciation | 164 | 184 | -20 |  | 658 | 741 | -83 |  |
| Home Office: | Stock-based compensation | 2,746 | 2,394 | 352 |  | 8,655 | 8,318 | 337 |  |
| Home Office: | Adjusted EBITDA | -11,996 | -7,522 | -4,474 | -59.5% | -34,530 | -26,971 | -7,559 | -28.0% |
| Covista: | Net income (GAAP) | 71,721 | 54,212 | 17,509 | 32.3% | 251,566 | 237,065 | 14,501 | 6.1% |
| Covista: | Loss (income) from discontinued operations | 439 | 250 | 189 |  | 15,809 | -4,388 | 20,197 |  |
| Covista: | Interest expense | 9,799 | 10,853 | -1,054 |  | 45,435 | 52,318 | -6,883 |  |
| Covista: | Other income, net | -2,756 | -2,511 | -245 |  | -7,178 | -9,290 | 2,112 |  |
| Covista: | Provision for income taxes | 16,240 | 14,121 | 2,119 |  | 77,744 | 65,837 | 11,907 |  |
| Covista: | Depreciation and amortization | 18,732 | 15,086 | 3,646 |  | 72,253 | 59,165 | 13,088 |  |
| Covista: | Stock-based compensation | 10,113 | 10,409 | -296 |  | 41,216 | 41,590 | -374 |  |
| Covista: | Restructuring expense | 1,101 | 388 | 713 |  | 6,329 | 3,314 | 3,015 |  |
| Covista: | Litigation reserve |  |  |  |  |  | -5,550 | 5,550 |  |
| Covista: | Asset impairments |  |  |  |  |  | 6,442 | -6,442 |  |
| Covista: | Strategic advisory costs | 1,530 | 6,900 | -5,370 |  | 18,562 | 12,000 | 6,562 |  |
| Covista: | Loss on assets held for sale |  | 490 | -490 |  |  | 490 | -490 |  |
| Covista: | Debt modification costs |  |  |  |  |  | 712 | -712 |  |
| Covista: | Adjusted EBITDA (non-GAAP) | 126,919 | 110,198 | 16,721 | 15.2% | 521,736 | 459,705 | 62,031 | 13.5% |
| Covista: | Adjusted EBITDA margin (non-GAAP) | 25.3% | 24.1% |  |  | 26.7% | 25.7% |  |  |

### Income Statement (Three Months Ended — Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.)

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Diluted earnings per share (GAAP) | 2.06 | 1.44 | 7.04 | 6.18 |

### Income Statement ((in thousands))

| | Year Ended – June 30, 2026 | June 30, 2026 |
|---|---:|---:|
| Covista: | Net income (GAAP) | 251,566 |  |
| Covista: | Loss from discontinued operations | 15,809 |  |
| Covista: | Interest expense | 45,435 |  |
| Covista: | Other income, net | -7,178 |  |
| Covista: | Provision for income taxes | 77,744 |  |
| Covista: | Depreciation and amortization | 72,253 |  |
| Covista: | Stock-based compensation | 41,216 |  |
| Covista: | Restructuring expense | 6,329 |  |
| Covista: | Strategic advisory costs | 18,562 |  |
| Covista: | Adjusted EBITDA (non-GAAP) | 521,736 |  |
| Covista: | Total long-term debt principal |  | 673,000 |
| Covista: | Less: Cash and cash equivalents |  | -406,316 |
| Covista: | Net debt (non-GAAP) |  | 266,684 |
| Covista: | Net leverage (non-GAAP) |  | 0.5x |

### Balance Sheet ((in thousands))

| | June 30, – 2026 | June 30, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 406,316 | 199,601 |
| Current assets: | Restricted cash | 1,438 | 1,563 |
| Current assets: | Accounts and financing receivables, net | 169,561 | 146,189 |
| Current assets: | Prepaid expenses and other current assets | 75,126 | 68,837 |
| Current assets: | Total current assets | 652,441 | 416,190 |
| Noncurrent assets: | Property and equipment, net | 302,649 | 256,131 |
| Noncurrent assets: | Operating lease assets | 204,364 | 191,194 |
| Noncurrent assets: | Deferred income taxes |  | 32,956 |
| Noncurrent assets: | Intangible assets, net | 754,254 | 765,474 |
| Noncurrent assets: | Goodwill | 961,262 | 961,262 |
| Noncurrent assets: | Other assets, net | 137,738 | 129,145 |
| Noncurrent assets: | Total noncurrent assets | 2,360,267 | 2,336,162 |
| Noncurrent assets: | Total assets | 3,012,708 | 2,752,352 |
| Current liabilities: | Accounts payable | 124,763 | 105,017 |
| Current liabilities: | Accrued payroll and benefits | 78,669 | 76,374 |
| Current liabilities: | Accrued liabilities | 94,364 | 77,286 |
| Current liabilities: | Deferred revenue | 259,125 | 214,091 |
| Current liabilities: | Current operating lease liabilities | 34,799 | 35,159 |
| Current liabilities: | Current portion of long-term debt | 5,100 |  |
| Current liabilities: | Total current liabilities | 596,820 | 507,927 |
| Noncurrent liabilities: | Long-term debt | 657,750 | 552,669 |
| Noncurrent liabilities: | Long-term operating lease liabilities | 207,846 | 186,172 |
| Noncurrent liabilities: | Deferred income taxes | 61,782 | 31,856 |
| Noncurrent liabilities: | Other liabilities | 42,325 | 40,103 |
| Noncurrent liabilities: | Total noncurrent liabilities | 969,703 | 810,800 |
| Noncurrent liabilities: | Total liabilities | 1,566,523 | 1,318,727 |
| Commitments and contingencies | Total shareholders' equity | 1,446,185 | 1,433,625 |
| Commitments and contingencies | Total liabilities and shareholders' equity | 3,012,708 | 2,752,352 |

### Cash Flow (Year Ended June 30, — (in thousands))

| | Year Ended June 30, – 2026 | Year Ended June 30, – 2025 |
|---|---:|---:|
| Operating activities: | Net income | 251,566 | 237,065 |
| Operating activities: | Loss (income) from discontinued operations | 15,809 | -4,388 |
| Operating activities: | Income from continuing operations | 267,375 | 232,677 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Stock-based compensation | 41,216 | 41,590 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization and impairments to operating lease assets | 27,946 | 32,543 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation | 43,850 | 40,702 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of acquired intangible assets | 11,220 | 11,220 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization and write-off of debt discount and issuance costs | 7,621 | 5,985 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Provision for credit losses | 68,765 | 63,237 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | 68,352 | 18,413 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Loss on disposals and impairments of property and equipment | 743 | 2,527 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Gain on investments | -1,720 | -1,074 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Loss on assets held for sale |  | 490 |
| Changes in assets and liabilities: | Accounts and financing receivables | -89,263 | -80,820 |
| Changes in assets and liabilities: | Prepaid expenses and other current assets | 8,423 | 5,546 |
| Changes in assets and liabilities: | Cloud computing implementation assets | -13,954 | -32,823 |
| Changes in assets and liabilities: | Accounts payable | 6,192 | 140 |
| Changes in assets and liabilities: | Accrued payroll and benefits | 2,494 | 5,144 |
| Changes in assets and liabilities: | Accrued liabilities | -9,697 | -15,948 |
| Changes in assets and liabilities: | Deferred revenue | 50,925 | 34,273 |

### Cash Flow (Twelve Months Ended — (in thousands))

| | Twelve Months Ended – FY25 – Q4 | Twelve Months Ended – FY26 – Q1 | Twelve Months Ended – FY26 – Q2 | Twelve Months Ended – FY26 – Q3 | Twelve Months Ended – FY26 – Q4 |
|---|---:|---:|---:|---:|---:|
| Net cash provided by operating activities-continuing operations (GAAP) | 333,734 | 374,796 | 427,890 | 406,335 | 470,796 |
| Capital expenditures | -50,327 | -55,936 | -59,880 | -69,872 | -77,696 |
| Free cash flow (non-GAAP) | 283,407 | 318,860 | 368,010 | 336,463 | 393,100 |
